ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism
ORIGINAL ARTICLE

Evaluation of DNA Damage in Patients with a Neuroendocrine Tumor
Nöroendokrin Tümörlü Hastalarda DNA Hasarının Değerlendirilmesi
Doi: 10.25179/tjem.2019-65610 - Makale Dili: EN
Turk J Endocrinol Metab 2019;23:105-111
ABSTRACT
Objective: Neuroendocrine tumors develop from the neuroendocrine cells of the endocrine system. As these tumors are extremely slow growing compared with other cancers, they often take years to reach a measurable dimension, thus leading to the late diagnosis, which has adverse effects on the survival and quality of life of patients. There is a link between many types of cancer and genomic instability, thus the markers associated with genomic instability can be used for early diagnosis of the disease or cancer-related changes. Comet assay is the most commonly used method to test genomic instability or DNA damage. To the best of our knowledge, no data are available on DNA damage in patients with neuroendocrine tumors. This study aimed to investigate the possible risk of DNA damage in a patient with neuroendocrine tumors using the comet assay. Material and Methods: The study included 23 patients with neuroendocrine tumors and 20 age-and sex-matched healthy participants. The DNA damage was determined using the comet assay for leukocytes obtained from the peripheral blood samples of patients and control participants. Results: We found that the DNA damage was markedly higher in the patients with neuroendocrine tumors than control participants (p˂0.05). Conclusion: Our data suggest that genomic instability contributes to the development of neuroendocrine tumors. However, further investigations are needed to support our results, as it is a preliminary report on DNA damage risk in patients with NETs.
ÖZET
Amaç: Nöroendokrin tümörler endokrin sistemin nöroendokrin hücrelerinden oluşan tümör grubunu temsil etmektedir. Bunların çoğu diğer kanserlere kıyasla çok yavaş büyür, belirtilere neden olmaları yıllar sürer ve geç evrede tanı konur. Genetik değişiklikler ile kanser arasında bir ilişkinin varlığı birçok çalışmayla desteklenmiş olup, genomik kararsızlık ile ilişkilendirilmiş belirteçlerin birçok hastalığın erken tanısında kullanılmasının yararlı olabileceği ileri sürülmektedir. Komet tekniği, genomik karasızlık/DNA hasarını test etmek için en sık kullanılan yöntemdir. Bildiğimiz kadarıyla, nöroendokrin tümörlü hastalarda genomik DNA hasarı ilgili herhangi bir veri bulunmamaktadır. Çalışmamızda, komet yöntemi ile tedavi almayan nöroendokrin tümörlü hastalarda olası DNA hasarlarının araştırılması amaçlanmıştır. Gereç ve Yöntemler: Araştırmamız, nöroendokrin tümörler teşhisi konmuş ve herhangi bir tedavi almamış 23 hastada ve bu hastalara benzer yaş ve cinsiyette olan 20 sağlıklı kişide yapıldı. Hasta ve sağlıklı kontrollerden alınan periferal kan örneklerinden elde edilen lökositlerinde DNA hasarı komet assay yöntemiyle belirlendi. Bulgular: Nöroendokrin tümörlü hastalarda DNA hasar oranının sağlıklı kişilere göre önemli seviyede yüksek olduğu bulundu (p˂0.05). Sonuç: Verilerimiz, genomik kararsızlığın nöroendokrin tümörlerin oluşuma katkıda bulunabileceğini göstermektedir. Fakat, sunulan çalışma literatürde bir ilk olduğundan, çalışmamızı desteklemek için daha fazla hasta sayısı ile yapılacak araştırmalara gerek olduğu düşünülmektedir.
KAYNAKLAR
  1. Öberg K. The genetics of neuroendocrine tumors. Semin Oncol. 2013;40:37-44. [Crossref] [PubMed]
  2. Paz MFCJ, de Alencar MVOB, Gomes Junior AL, da Conceição Machado K, Islam MT, Ali ES, Shill MC, Ahmed MI, Uddin SJ, da Mata AMOF, de Carvalho RM, da Conceição Machado K, Sobral ALP, da Silva FCC, de Castro E Souza JM, Arcanjo DDR, Ferreira PMP, Mishra SK, da Silva J, de Carvalho Melo-Cavalcante AA. Correlations between risk factors for breast cancer and genetic instability in cancer patients-a clinical perspective study. Front Genet. 2018;8:236. [Crossref] [PubMed] [PMC]
  3. Cuceu C, Colicchio B, Jeandidier E, Junker S, Plassa F, Shim G, Mika J, Frenzel M, Al Jawhari M, Hempel WM, O’Brien G, Lenain A, Morat L, Girinsky T, Dieterlen A, Polanska J, Badie C, Carde P, M’Kacher R. Independent mechanisms lead to genomic instability in hodgkin lymphoma: microsatellite or chromosomal instability. Cancers (Basel). 2018;10. [Crossref] [PubMed] [PMC]
  4. van Jaarsveld RH, Kops GJPL. Difference makers: chromosomal instability versus aneuploidy in cancer. Trends Cancer. 2016;561-571. [Crossref] [PubMed]
  5. Gunasekarana V, Raj GV, Chand P. A comprehensive review on clinical applications of comet assay. J Clin Diagn Res. 2015;9:GE01-5. [Crossref] [PubMed] [PMC]
  6. Usman M, Volpi EV. DNA damage in obesity: initiator, promoter and predictor of cancer. Mutat Res. 2018;778:23-37. [Crossref] [PubMed]
  7. Konstantinopoulos PA, Matulonis UA. Targeting DNA damage response and repair as a therapeutic strategy for ovarian cancer. Hematol Oncol Clin North Am. 2018;32:997-1010. [Crossref] [PubMed]
  8. Silveira Zavalhia L, Weber Medeiros A, Oliveira Silva A, Vial Roehe A. Do FHIT gene alterations play a role in human solid tumors? Asia Pac J Clin Oncol. 2018;14:e214-e223. [Crossref] [PubMed]
  9. Cortés-Gutiérrez EI, D'ávila-Rodríguez MI, CerdaFlores RM. Chromosomal damage as prognosis marker in cervical carcinogenesis. Tsitol Genet. 2014;48:54-63. [Crossref] [PubMed]
  10. Kushwaha S, Vikram A, Trivedi PP, Jena GB. Endo III and FPG modified comet assay as biomarkers for the detectionof oxidative DNA damage in rats with experimentally induced diabetes. Mutat Res. 2011;726:242-250. [Crossref] [PubMed]
  11. Fikrová P, Stětina R, Hronek M, Hyšpler R, Tichá A, Zadák Z. Application of the comet assay method in clinical studies. Wien Klin Wochenschr. 2011;123: 693-699. [Crossref] [PubMed]
  12. Di Domenico A, Wiedmer T, Marinoni I, Perren A. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017;24: R315-R334. [Crossref] [PubMed]
  13. Cives M, Simone V, Rizzo FM, Silvestris F. NETs: organ-related epigenetic derangements and potential clinical applications. Oncotarget. 2016;7:5741457429. [Crossref] [PubMed] [PMC]
  14. Crona J, Skogseid B. GEP-NETS UPDATE: genetics of neuroendocrine tumors. Eur J Endocrinol. 2016;174:275-290. [Crossref] [PubMed]
  15. Devecioglu TY, Aydogan F, Omurtag GZ, Bese NS, Sardas S. Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole. North Clin Istanb. 2018;5:6-13.
  16. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184-191. [Crossref]
  17. Khisroon M, Gul A, Khan A, Ali N, Zaidi F, Rasheed SB, Ahmadullah, Akbar H. Comet assay based DNA evaluation of fuel filling stations and automobile workshops workers from Khyber Pakhtunkhwa istan. J Occup Med Toxicol. 2015;10:27. [Crossref] [PubMed] [PMC]
  18. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol. 2004;26:249-261. [Crossref]
  19. Mescka CP, Wayhs CA, Guerreiro G, Manfredini V, Dutra-Filho CS, Vargas CR. Prevention of DNA damage by L-carnitine induced by metabolites accumulated in maple syrup urine disease in human peripheral leukocytes in vitro. Gene. 2014;548:294-298. [Crossref] [PubMed]
  20. Cives M, Strosberg J. An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park). 2014;28:749-756, 758.
  21. Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435-e446. [Crossref]
  22. Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, García-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP. Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene. 2017;36:1899-1907. [Crossref] [PubMed]
  23. Bergsland EK. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Semin Oncol. 2013;40:1-3. [Crossref] [PubMed]
  24. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Nagaraj SH, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Davì MV, Landoni L, Malpaga A, Miotto M, Whitehall VL, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LM, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65-71. [Crossref] [PubMed]
  25. Bausinger J, Speit G. Induction and repair of DNA damage measured by the comet assay in human T lymphocytes separated by immunomagnetic cell sorting. Mutat Res. 2014;769:42-48. [Crossref] [PubMed]
  26. García O, Romero I, González JE, Moreno DL, Cuétara E, Rivero Y, Gutiérrez A, Pérez CL, Alvarez A, Carnesolta D, Guevara I. Visual estimation of the percentage of DNA in the tail in the comet assay: evaluation of different approaches in an intercomparison exercise. Mutat Res. 2011;720:14-21. [Crossref] [PubMed]
  27. Maronpot RR, Hobbs CA, Hayashi SM. Role of pathology peer review in interpretation of the comet assay. J Toxicol Pathol. 2018;31:155-161. [Crossref] [PubMed] [PMC]
  28. Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146:453-460.e5. [Crossref] [PubMed]
  29. Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris TJ, Salomoni P, Luong TV, Davidson B, Beck S, Thirlwell C. Epigenetic dysregulation and poorer prognosis in DAXXdeficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015;22:L13-18. [Crossref] [PubMed] [PMC]
  30. Karpathakis A, Dibra H, Pipinikas C, Feber A, Morris T, Francis J, Oukrif D, Mandair D, Pericleous M, Mohmaduvesh M, Serra S, Ogunbiyi O, Novelli M, Luong T, Asa SL, Kulke M, Toumpanakis C, Meyer T, Caplin M, Meyerson M, Beck S, Thirlwell C. Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor. Clin Cancer Res. 2016;22:250-258. [Crossref] [PubMed]
  31. Marinoni I, Wiederkeher A, Wiedmer T, Pantasis S, Di Domenico A, Frank R, Vassella E, Schmitt A, Perren A. Hypo-methylation mediates chromosomal instability in pancreatic NET. Endocr Relat Cancer. 2017;24:137-146. [Crossref] [PubMed]
  32. Hammond D, Zeng K, Espert A, Bastos RN, Baron RD, Gruneberg U, Barr FA. Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A. J Cell Sci. 2013;126:3429-3440. [Crossref] [PubMed]
  33. Schupp N, Stopper H, Heidland A. DNA damage in chronic kidney disease: evaluation of clinical biomarkers. Oxid Med Cell Longev. 2016;2016: 3592042. [Crossref] [PubMed] [PMC]
  34. Ji S, Yang W, Liu J, Zhao J, Chen L, Ni Q, Long J, Yu X. High throughput gene sequencing reveals altered landscape in DNA damage responses and chromatin remodeling in sporadic pancreatic neuroendocrine tumors. Pancreatology. 2018;18:318-327. [Crossref] [PubMed]